148 related articles for article (PubMed ID: 27203461)
1. Fluorescent peptide biosensor for monitoring CDK4/cyclin D kinase activity in melanoma cell extracts, mouse xenografts and skin biopsies.
Prével C; Pellerano M; González-Vera JA; Henri P; Meunier L; Vollaire J; Josserand V; Morris MC
Biosens Bioelectron; 2016 Nov; 85():371-380. PubMed ID: 27203461
[TBL] [Abstract][Full Text] [Related]
2. Fluorescent Peptide Biosensor for Probing CDK6 Kinase Activity in Lung Cancer Cell Extracts.
Soamalala J; Diot S; Pellerano M; Blanquart C; Galibert M; Jullian M; Puget K; Morris MC
Chembiochem; 2021 Mar; 22(6):1065-1071. PubMed ID: 33112024
[TBL] [Abstract][Full Text] [Related]
3. Lanthanide-based peptide biosensor to monitor CDK4/cyclin D kinase activity.
González-Vera JA; Bouzada D; Bouclier C; Eugenio Vázquez M; Morris MC
Chem Commun (Camb); 2017 Jun; 53(45):6109-6112. PubMed ID: 28530267
[TBL] [Abstract][Full Text] [Related]
4. Frequent Genetic Aberrations in the CDK4 Pathway in Acral Melanoma Indicate the Potential for CDK4/6 Inhibitors in Targeted Therapy.
Kong Y; Sheng X; Wu X; Yan J; Ma M; Yu J; Si L; Chi Z; Cui C; Dai J; Li Y; Yu H; Xu T; Tang H; Tang B; Mao L; Lian B; Wang X; Yan X; Li S; Guo J
Clin Cancer Res; 2017 Nov; 23(22):6946-6957. PubMed ID: 28830923
[No Abstract] [Full Text] [Related]
5. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations.
Chudnovsky Y; Adams AE; Robbins PB; Lin Q; Khavari PA
Nat Genet; 2005 Jul; 37(7):745-9. PubMed ID: 15951821
[TBL] [Abstract][Full Text] [Related]
6. The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma.
Sheppard KE; McArthur GA
Clin Cancer Res; 2013 Oct; 19(19):5320-8. PubMed ID: 24089445
[TBL] [Abstract][Full Text] [Related]
7. Ablation of epidermal RXRα in cooperation with activated CDK4 and oncogenic NRAS generates spontaneous and acute neonatal UVB induced malignant metastatic melanomas.
Chagani S; Wang R; Carpenter EL; Löhr CV; Ganguli-Indra G; Indra AK
BMC Cancer; 2017 Nov; 17(1):736. PubMed ID: 29121869
[TBL] [Abstract][Full Text] [Related]
8. Fluorescent peptide biosensor for probing the relative abundance of cyclin-dependent kinases in living cells.
Kurzawa L; Pellerano M; Coppolani JB; Morris MC
PLoS One; 2011; 6(10):e26555. PubMed ID: 22028905
[TBL] [Abstract][Full Text] [Related]
9. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
Bartkova J; Lukas J; Guldberg P; Alsner J; Kirkin AF; Zeuthen J; Bartek J
Cancer Res; 1996 Dec; 56(23):5475-83. PubMed ID: 8968104
[TBL] [Abstract][Full Text] [Related]
10. TP-2Rho Is a Sensitive Solvatochromic Red-Shifted Probe for Monitoring the Interactions between CDK4 and Cyclin D.
Pellerano M; Naud-Martin D; Peyressatre M; Prével C; Teulade-Fichou MP; Morris M; Mahuteau-Betzer F
Chembiochem; 2016 Apr; 17(8):737-44. PubMed ID: 26946188
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-206 induces G1 arrest in melanoma by inhibition of CDK4 and Cyclin D.
Georgantas RW; Streicher K; Luo X; Greenlees L; Zhu W; Liu Z; Brohawn P; Morehouse C; Higgs BW; Richman L; Jallal B; Yao Y; Ranade K
Pigment Cell Melanoma Res; 2014 Mar; 27(2):275-86. PubMed ID: 24289491
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the cyclin-dependent kinase inhibitory domain of the INK4 family as a model for a synthetic tumour suppressor molecule.
Fåhraeus R; Laín S; Ball KL; Lane DP
Oncogene; 1998 Feb; 16(5):587-96. PubMed ID: 9482104
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous knockdown of BRAF and expression of INK4A in melanoma cells leads to potent growth inhibition and apoptosis.
Zhao Y; Zhang Y; Yang Z; Li A; Dong J
Biochem Biophys Res Commun; 2008 Jun; 370(3):509-13. PubMed ID: 18402768
[TBL] [Abstract][Full Text] [Related]
14. Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer growth.
Bouclier C; Simon M; Laconde G; Pellerano M; Diot S; Lantuejoul S; Busser B; Vanwonterghem L; Vollaire J; Josserand V; Legrand B; Coll JL; Amblard M; Hurbin A; Morris MC
Theranostics; 2020; 10(5):2008-2028. PubMed ID: 32104498
[TBL] [Abstract][Full Text] [Related]
15. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.
Young RJ; Waldeck K; Martin C; Foo JH; Cameron DP; Kirby L; Do H; Mitchell C; Cullinane C; Liu W; Fox SB; Dutton-Regester K; Hayward NK; Jene N; Dobrovic A; Pearson RB; Christensen JG; Randolph S; McArthur GA; Sheppard KE
Pigment Cell Melanoma Res; 2014 Jul; 27(4):590-600. PubMed ID: 24495407
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical analysis of the D-type cyclin-dependent kinases Cdk4 and Cdk6, using a series of monoclonal antibodies.
Lukas C; Jensen SK; Bartkova J; Lukas J; Bartek J
Hybridoma; 1999 Jun; 18(3):225-34. PubMed ID: 10475236
[TBL] [Abstract][Full Text] [Related]
17. Proteins involved in pRb and p53 pathways are differentially expressed in thin and thick superficial spreading melanomas.
de Sá BC; Fugimori ML; Ribeiro Kde C; Duprat Neto JP; Neves RI; Landman G
Melanoma Res; 2009 Jun; 19(3):135-41. PubMed ID: 19369901
[TBL] [Abstract][Full Text] [Related]
18. Predicting functional significance of cancer-associated p16(INK4a) mutations in CDKN2A.
McKenzie HA; Fung C; Becker TM; Irvine M; Mann GJ; Kefford RF; Rizos H
Hum Mutat; 2010 Jun; 31(6):692-701. PubMed ID: 20340136
[TBL] [Abstract][Full Text] [Related]
19. Altered expression of cell cycle regulators Cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas.
Bachmann IM; Straume O; Akslen LA
Int J Oncol; 2004 Dec; 25(6):1559-65. PubMed ID: 15547691
[TBL] [Abstract][Full Text] [Related]
20. Fluorescent Peptide Biosensors for Probing CDK Kinase Activity in Cell Extracts.
Pellerano M; Morris MC
Methods Mol Biol; 2021; 2329():39-50. PubMed ID: 34085214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
